SB4 (an etanercept biosimilar)	etanercept (ETN)	incidence of antidrug antibody development up to week 24 - Patients with moderate to severe rheumatoid arthritis (RA) despite methotrexate (MTX) treatment	1453	1565	the incidence of antidrug antibody development up to week 24 was lower in SB4 compared with ETN (0.7% vs 13.1%).
SB4 (an etanercept biosimilar)	etanercept (ETN)	ACR70 (American College of Rheumatology 70% response rate at week 24 in the PPS and FAS - Patients with moderate to severe rheumatoid arthritis (RA) despite methotrexate (MTX) treatment	14300	14401	The ACR50 and ACR70 response rates at week 24 in the PPS and FAS were equivalent between SB4 and ETN.
SB4 (an etanercept biosimilar)	etanercept (ETN)	incidence of treatment-emergent adverse events - Patients with moderate to severe rheumatoid arthritis (RA) despite methotrexate (MTX) treatment	1365	1447	The incidence of treatment-emergent adverse events was comparable (55.2% vs 58.2%)
SB4 (an etanercept biosimilar)	etanercept (ETN)	ACR50 (American College of Rheumatology 50% response rate at week 24 in the PPS and FAS - Patients with moderate to severe rheumatoid arthritis (RA) despite methotrexate (MTX) treatment	14300	14401	The ACR50 and ACR70 response rates at week 24 in the PPS and FAS were equivalent between SB4 and ETN.
SB4 (an etanercept biosimilar)	etanercept (ETN)	ACR70 (American College of Rheumatology 70% response rate at week 24 in the PPS and FAS - Patients with moderate to severe rheumatoid arthritis (RA) despite methotrexate (MTX) treatment	14314	14400	ACR70 response rates at week 24 in the PPS and FAS were equivalent between SB4 and ETN
SB4 (an etanercept biosimilar)	etanercept (ETN)	therapeutic equivalence - Patients with moderate to severe rheumatoid arthritis (RA) despite methotrexate (MTX) treatment	1081	1292	The 95% CI of the adjusted treatment difference was −9.41% to 4.98%, which is completely contained within the predefined equivalence margin of −15% to 15%, indicating therapeutic equivalence between SB4 and ETN.
SB4 (an etanercept biosimilar)	etanercept (ETN)	ACR50 (American College of Rheumatology 50% response rate at week 24 in the PPS and FAS - Patients with moderate to severe rheumatoid arthritis (RA) despite methotrexate (MTX) treatment	14300	14400	The ACR50 and ACR70 response rates at week 24 in the PPS and FAS were equivalent between SB4 and ETN
SB4 (an etanercept biosimilar)	etanercept (ETN)	incidence of antidrug antibody development up to week 24 - Patients with moderate to severe rheumatoid arthritis (RA) despite methotrexate (MTX) treatment	18858	19107	The incidence of ADA was significantly lower in SB4 compared with ETN. Two (0.7%) patients in SB4 and 39 (13.1%) patients in ETN tested positive at least once up to week 24 (p<0.001), and only one sample from the ETN group had neutralising capacity.
